ADAM-9 (MDC-9/meltrin-γ), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the α vβ5 integrin

Blood

Volumn 107, Issue 8, 2006, Pages 3271-3278

  Karadag, Abdullah ^a   Zhou, Min ^b   Croucher, Peter I ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 9 PROTEIN; ALPHAVBETA5 INTEGRIN; DISINTEGRIN; HETERODIMER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTEGRIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; JANUS KINASE 2; MESSENGER RNA; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PROTEIN ANTIBODY; PROTEIN INHIBITOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ARTICLE; CELL GROWTH; CELL STIMULATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RNA ANALYSIS; SIGNAL TRANSDUCTION; TIME;

EID: 33645745595     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-09-3830     Document Type: Article

References (43)

1. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-234.
2. Klein B, Zhang XG, Jourdan M, et al. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw. 1990;1:193-201.
3. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85:863-872.
4. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162:248-255.
5. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood. 2001;98:3534-3540.
6. Farrugia AN, Atkins GJ, To LB, et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res. 2003;63:5438-5445.
7. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527-3533.
8. Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001;98:11581-11586.
9. Zhou M, Graham R, Russell G, Croucher PI. MDC-9 (ADAM-9/Meltrin gamma) functions as an adhesion molecule by binding the alpha(v)beta(5) integrin. Biochem Biophys Res Commun. 2001;280:574-580.
10. Wolfsberg TG, Primakoff P, Myles DG, White JM. ADAM, a novel family of membrane proteins containing A Disintegrin And Metalloprotease domain: multipotential functions in cell-cell and cellmatrix interactions. J Cell Biol. 1995;131:275-278.
11. Blobel CP. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell. 1997;90:589-592.
12. Huovila AP, Almeida EA, White JM. ADAMs and cell fusion. Curr Opin Cell Biol. 1996;8:692-699.
13. Black RA, White JM. ADAMs: focus on the protease domain. Curr Opin Cell Biol. 1998;10:654-659.
14. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. 2000;16:83-87.
15. Zhang XP, Kamata T, Yokoyama K, Puzon-McLaughlin W, Takada Y. Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3. J Biol Chem. 1998;273:7345-7350.
16. Nath D, Slocombe PM, Stephens PE, et al. Interaction of metargidin (ADAM-15) with alphavbeta3 and alpha5beta1 integrins on different haemopoietic cells. J Cell Sci. 1999;112:579-587.
17. Cho C, Bunch DO, Faure JE, et al. Fertilization defects in sperm from mice lacking fertilin beta. Science. 1998;281:1857-1859.
18. Evans JP, Schultz RM, Kopf GS. Mouse spermegg plasma membrane interactions: analysis of roles of egg integrins and the mouse sperm homologue of PH-30 (fertilin) beta. J Cell Sci. 1995;108:3267-3278.
19. Blobel CP, Wolfsberg TG, Turck CW, Myles DG, Primakoff P, White JM. A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature. 1992;356:248-252.
20. Bigler D, Takahashi Y, Chen MS, Almeida EA, Osbourne L, White JM. Sequence-specific interaction between the disintegrin domain of mouse ADAM 2 (fertilin beta) and murine eggs: role of the alpha(6) integrin subunit. J Biol Chem. 2000;275:11576-11584.
21. Chen H, Sampson NS. Mediation of sperm-egg fusion: evidence that mouse egg alpha6beta1 integrin is the receptor for sperm fertilin beta. Chem Biol. 1999;6:1-10.
22. Almeida EA, Huovila AP, Sutherland AE, et al. Mouse egg integrin alpha 6 beta 1 functions as a sperm receptor. Cell. 1995;81:1095-1104.
23. Eto K, Puzon-McLaughlin W, Sheppard D, Sehara-Fujisawa A, Zhang XP, Takada Y. RGDindependent binding of integrin alpha9beta1 to the ADAM-12 and -15 disintegrin domains mediates cell-cell interaction. J Biol Chem. 2000;275:34922-34930.
24. Cal S, Freije JM, Lopez JM, Takada Y, Lopez-Otin C. ADAM 23/MDC3, a human disintegrin that promotes cell adhesion via interaction with the alphavbeta3 integrin through an RGD-independent mechanism. Mol Biol Cell. 2000;11:1457-1469.
25. Nath D, Slocombe PM, Webster A, Stephens PE, Docherty AJ, Murphy G. Meltrin gamma(ADAM-9) mediates cellular adhesion through alpha(6)beta(1)- integrin, leading to a marked induction of fibroblast cell motility. J Cell Sci. 2000;113(Pt 12):2319-2328.
26. Karadag A, Scutt AM, Croucher PI. Human myeloma cells promote the recruitment of osteoblast precursors: mediation by interleukin-6 and soluble interleukin-6 receptor. J Bone Miner Res. 2000;15:1935-1943.
27. Karadag A, Oyajobi BO, Apperley JF, Russell RG, Croucher PI. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts. Br J Haematol. 2000;108:383-390.
28. Hargreaves PG, Wang F, Antcliff J, et al. Human myeloma cells shed the interleukin-6 receptor: inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor. Br J Haematol. 1998;101:694-702.
29. Holen I, Drury NL, Hargreaves PG, Croucher PI. Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells. Br J Haematol. 2001;114:414-421.
30. Barille S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood. 1995;86:3151-3159.
31. Smith JW, Vestal DJ, Irwin SV, Burke TA, Cheresh DA. Purification and functional characterization of integrin alpha v beta 5: an adhesion receptor for vitronectin. J Biol Chem. 1990;265:11008-11013.
32. Hu DD, Lin EC, Kovach NL, Hoyer JR, Smith JW. A biochemical characterization of the binding of osteopontin to integrins alpha v beta 1 and alpha v beta 5. J Biol Chem. 1995;270:26232-26238.
33. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myelomaderived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993;82:3712-3720.
34. Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994;84:2269-2277.
35. Patil C, Zhu X, Rossa C Jr, Kim YJ, Kirkwood KL. p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest. 2004;33:213-233.
36. Webb SJ, McPherson JR, Pahan K, Koka S. Regulation of TNF-alpha-induced IL-6 production in MG-63 human osteoblast-like cells. J Dent Res. 2002;81:17-22.
37. Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101:703-705.
38. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527.
39. Mainiero F, Colombara M, Antonini V, et al. p38 MAPK is a critical regulator of the constitutive and the beta4 integrin-regulated expression of IL-6 in human normal thymic epithelial cells. Eur J Immunol. 2003;33:3038-3048.
40. Dahle MK, Overland G, Myhre AE, et al. The phosphatidylinositol 3-kinase/protein kinase B signaling pathway is activated by lipoteichoic acid and plays a role in Kupffer cell production of interleukin-6 (IL-6) and IL-10. Infect Immun. 2004;72:5704-5711.
41. Wang XH, Yan GT, Wang LH, Hao XH, Zhang K, Xue H. The mediating role of cPLA2 in IL-1 beta and IL-6 release in LPS-induced HeLa cells. Cell Biochem Funct. 2004;22:41-44.
42. Gijon MA, Spencer DM, Siddiqi AR, Bonventre JV, Leslie CC. Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium: novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J Biol Chem. 2000;275:20146-20156.
43. Lai WC, Zhou M, Shankavaram U, Peng G, Wahl LM. Differential regulation of lipopolysaccharide-induced monocyte matrix metalloproteinase (MMP)-1 and MMP-9 by p38 and extracellular signal-regulated kinase 1/2 mitogen-activated protein kinases. J Immunol. 2003;170:6244-6249.